Emerging therapeutic targets in psoriasis

Current Opinion in Pharmacology

Volumn 4, Issue 3, 2004, Pages 306-310

  Bayliffe, Andrew I ^a   Brigandi, Richard A ^b   Wilkins, H Jeffrey ^b   Levick, Mark P ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ALEFACEPT; ANGIOGENIC FACTOR; BEXAROTENE; CADHERIN; CYCLOSPORIN; CYCLOSPORIN A; DITHRANOL; EFALIZUMAB; EMBREL; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 23; KERATINOCYTE GROWTH FACTOR; METHOTREXATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIMECROLIMUS; PROTEIN C JUN; REMICAIDE; RETINOIC ACID; RETINOID X RECEPTOR; TACALCITOL; TRANSCRIPTION FACTOR AP 2; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VITAMIN D DERIVATIVE;

CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EPIDERMIS CELL; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; PRIORITY JOURNAL; PSORIASIS; REVIEW; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DERMATOLOGIC AGENTS; HUMANS; KERATINOCYTES; PSORIASIS; TACROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 2342486219     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.02.003     Document Type: Review

References (54)

1. Travis L. Weinberg J.M. Medical backgrounder: psoriasis Drugs Today 38 2002 847-865
2. Lebwohl M. Psoriasis Lancet 361 2003 1197-1204
3. Callen J.P. Krueger G.G. Lebwohl M. McBurney E.I. Mease P. Menter A. Paller A.S. Pariser D.M. Weinblatt M. Zimmerman G. AAD consensus statement on psoriasis therapies J Am Acad Dermatol 9 2003 897-899
4. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents J Am Acad Dermatol 46 2002 1-23
5. Barker J.N. Genetic aspects of psoriasis Clin Exp Dermatol 26 2001 321-325
6. Hewett D. Samuelsson L. Polding J. Enlund F. Smart D. Cantone K. See C.G. Chadha S. Inerot A. Enerback C. et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localised single nucleotide polymorphism map Genomics 79 2002 305-314
7. Helms C. Cao L. Krueger J.G. Wijsman E.M. Chamian F. Gordon D. Heffernan M. Wright Daw J.A. Robarge J. Ott J. et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis Nat Genet 35 2003 349-356
8. Zhou X. Krueger J.G. Du F. Menter A. Wong W.H. Bowcock A.M. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,1000-element oligonucleotide array Physiol Genomics 13 2003 69-78
9. Takahashi H. Ibe M. Kinouchi M. Ishida-Yamamoto A. Hashimoto Y. Iizuka H. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation J Dermatol Sci 31 2003 21-28
10. Pol A. Bergers M. Schalkwijk J. Comparison of anti-proliferative effects of experimental and established anti-psoriatic drugs on human keratinocytes, using a simple 96-well-plate assay In Vitro Cell Dev Biol Anim 39 2003 36-42
11. Franssen M.E.J. Smit J.V. Van Erp P.E.J. Van de Kerkhof P.C.M. A multi-parameter flow cytometric analysis of the effect of bexarotene on the epidermis of the psoriatic lesion Br J Dermatol 149 2003 506-512
12. Ellis C.N. Varani J. Fisher G.J. Zeigler M.E. Pershadsingh H.A. Benson S.C. Chi Y. Kurtz T.W. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation Arch Dermatol 136 2000 609-616
13. Westergaard M. Henningsen J. Johansen C. Rasmussen S. Svendsen M.L. Jensen U.B. Shroder H.D. Staels B. Iversen L. Bolund L. et al. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid J Invest Dermatol 116 2001 702-712
14. Majewski S. Jablonska S. Do epidermodysplasia verruciformis human papillomaviruses contribute to malignant and benign epidermal proliferations? Arch Dermatol 138 2002 649-654
15. Mah A.C.E. Bodemer C. Descamps V. Mah A.C.I. Crickx B. De Prost Y. Favre M. High frequency of detection of human papillomaviruses associated with epidermodysplasia verruciformis in children with psoriasis Br J Dermatol 149 2003 819-825
16. Travers J.B. Norris D.A. Leung D.Y.M. The keratinocyte as a target for staphylococcal bacterial toxins J Invest Dermatol 6 2001 225-230
17. Baroni A. Paoletti I. Ruocco E. Agozzino M. Tufano M.A. Donnarumma G. Possible role of Malassezia furfur in psoriasis: modulation of TGF-beta-1, integrin, and HSP70 expression in human keratinocytes and in the skin of psoriasis-affected patients J Cutan Pathol 31 2004 35-42
18. Doi H. Shibata M.A. Kiyokane K. Otsuki Y. Down regulation of TGF beta isoforms and their receptors contributes to keratinocyte hyperproliferation in psoriasis vulgaris J Dermatol Sci 33 2003 7-16
19. Edmondson S.R. Thumiger S.P. Werther G.A. Wraight C.J. Epidermal homeostasis: The role of the growth hormone and insulin-like growth factor systems Endocr Rev 24 2003 737-764
20. Zhou S. Matsuyoshi N. Takeuchi T. Ohtsuki Y. Miyachi Y. Reciprocal altered expression of T-cadherin and P-cadherin in psoriasis vulgaris Br J Dermatol 149 2003 268-273
21. Matsuzaka Y. Okamoto K. Tsuji H. Mabuchi T. Ozawa A. Tamiya G. Inoko H. Identification of the hRDH-E2 gene, a novel member of the SDR family, and its increased expression in psoriatic lesion Biochem Biophys Res Commun 297 2002 1171-1180
22. Oyama N. Takahashi H. Tojo M. Iwatsuki K. Iizuka H. Nakamura K. Homma Y. Kaneko F. Different properties of three isoforms (alpha, beta, and gamma) of transcription factor AP-2 in the expression of human keratinocyte genes Arch Dermatol Res 294 2002 273-280
23. Wang Y.N. Chang W.C. Induction of disease-associated keratin 16 gene expression by epidermal growth factor is regulated through cooperation of transcription factors Sp1 and c-Jun J Biol Chem 278 2003 45848-45857
24. Werner S. Smola H. Paracrine regulation of keratinocyte proliferation and differentiation Trends Cell Biol 11 2001 143-146
25. Takahashi H. Ibe M. Nakamura S. Ishida-Yamamoto A. Hashimoto Y. Iizuka H. Extra-cellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis J Dermatol Sci 30 2002 94-99
26. Krueger G.G. Callis K.P. Development and use of alefacept to treat psoriasis J Am Acad Dermatol 49 2003 S87-S97
27. Leonardi C.L. Efalizumab: an overview J Am Acad Dermatol 49 2003 S98-S104
28. Goffe B. Clay Cather J. Etanercept: an overview J Am Acad Dermatol 49 2003 S105-S111
29. Gottlieb A.B. Infliximab for psoriasis J Am Acad Dermatol 49 2003 S112-S117
30. Rappersberger K. Komar M. Ebelin M.-E. Scott G. Burtin P. Greig G. Kehren J. Chibout S.-D. Cordier A. Holter W. et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated J Invest Dermatol 119 2002 876-887
31. Ghoreschi K. Thomas P. Breit S. Dugas M. Mailhammer R. van Eden W. van der Zee R. Biedermann T. Prinz J. Mack M. et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease Nat Med 9 2003 40-46
32. Villadsen L.S. Schuurman J. Beurskens F. Dam T.N. Dagnæs-Hansen F. Skov L. Rygaard J. Voorhorst-Ogink M.M. Gerritsen A.F. van Dijk M.A. et al. Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model J Clin Invest 112 2003 1571-1579
33. Aggarwal S. Ghilard N. Xie M.-H. De Sauvage F.J. Gurney A. IL-23 promotes a distinct CD4 T cell activation status characterised by the production of IL-17 J Biol Chem 278 2003 1910-1914
34. Kopp T. Lenz P. Bello-Fernandez C. Kastelein R.A. Kupper T.S. Stingl G. IL-23 production by co-secretion of endogenous p19 and transgenic p40 in K14/p40 transgenic mice: evidence for enhanced cutaneous immunity J Immunol 170 2003 5438-5444
35. Cua D.J. Sherlock J. Chen Y. Murphy C.A. Joyce B. Seymour B. Lucian L. To W. Kwan S. Churakova T. et al. IL-23 rather than IL-12 is the critical cytokine for autoimmune inflammation of the brain Nature 421 2003 744-748
36. Lee E. Trepicchio W.L. Oestricher J.L. Pittman D. Wang F. Chamian F. Dhodapkar M. Krueger J.G. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris J Exp Med 199 2004 125-130
37. Blumberg H. Conkin D. Xu W. Grossman A. Brender T. Carollo S. Eagan M. Foster D. Haldeman B.A. Hammond A. et al. Interleukin 20: discovery, receptor identification and role in epidermal function Cell 104 2001 9-19
38. Bhushan M. Young H. Brenchley P.E.C. Griffiths C.E.M. Recent advances in cutaneous angiogenesis Br J Dermatol 147 2002 418-425
39. Velasco P. Lange-Asschenfeldt B. Dermatological aspects of angiogenesis Br J Dermatol 147 2002 841-852
40. Creamer D. Sullivan D. Bicknell R. Barker J. Angiogenesis in psoriasis Angiogenesis 5 2002 231-236
41. Suomela S. Kariniemi A.-L. Impola U. Karvonen S.-L. Snellman E. Uurasmaa T. Peltonen J. Saarialho-Kere U. Matrix metalloproteinase-19 is expressed by keratinocytes in psoriasis Acta Derm Venereol 83 2003 108-114
42. Nielson H.J. Christensen I.J. Svendsen M.N. Hansen U. Werther K. Brunner N. Petersen L.J. Kristensen J.K. Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis Inflamm Res 51 2002 563-567
43. Kuroda K. Sapadin A. Shoji T. Fleischmajer R. Lebwohl M. Altered expression of angiopoietins and tie-2 endothelium receptor in psoriasis J Invest Dermatol 116 2001 713-720
44. Pestelli E. Floriani I. Fabbri P. Caproni M. Cetrizine modulates adhesion molecule expression in a double blind controlled study conducted in psoriasis patients Int J Tissue React 25 2003 1-8
45. Bhushan M. McLaughlin B. Weiss J.B. Griffiths C.E.M. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis Br J Dermatol 141 1999 1054-1060
46. Creamer D. Allen M. Jaggar R. Stevens R. Bicknell R. Barker J. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor Arch Dermatol 138 2002 791-796
47. Xia Y.-P. Li B. Hylton D. Detmar M. Yancopoulos G.D. Rudge J.S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis Blood 102 2003 161-168
48. Reinders M.E.J. Sho M. Izawa A. Wang P. Mukhopadhyay D. Koss K. Geehan C.S. Luster A.D. Sayegh M.H. Briscoe D.M. Proinflammatory functions of vascular endothelial growth factor in alloimmunity J Clin Invest 112 2003 1655-1665
49. Young H.S. Summers A.M. Bhushan M. Brenchley P.E.C. Griffiths C.E.M. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset J Invest Dermatol 122 2004 209-215
50. Lambrechts D. Storkebaum E. Morimoto M. Del-Favero J. Desmet F. Marklund S.L. Wyn S. Thijs V. Andersson J. van Marion I. et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death Nat Genet 34 2003 383-394
51. Sauder D.N. DeKoven J. Champagne P. Croteau D. DuPont E. Neovastat (AE941), an inhibitor of angiogenesis: randomized phase I/II clinical trial results in patients with plaque psoriasis J Am Acad Dermatol 47 2002 535-541
52. Gould A.R. Sharp P.J. Smith D.R. Stegink A.J. Chase C.J. Kovacs J.C. Penglis S. Chatterton B.E. Bunn C.L. Increased permeability of psoriatic skin to the protein, plasminogen activator inhibitor 2 Arch Dermatol Res 295 2003 249-254
53. White P.J. Atley L.M. Wraight C.J. Antisense oligonucleotide treatments for psoriasis Expert Opin Biol Ther 4 2004 75-81
54. Wary K.K. Thakker G.D. Humtsoe J.O. Yang J. Analysis of VEGF-responsive genes involved in the activation of endothelial cells Mol Cancer 2 2003 25-37